Objective To explore the relationship between serum miR-183-3p and miR-495-3p expression and clinical pathological characteristics and prognosis of esophageal cancer patients. Methods A total of 105 patients with esophageal cancer admitted to The Third Medical Center of the General Hospital of the People's Liberation Army from December 2017 to December 2020 as the esophageal cancer group, and another 105 healthy individuals who underwent physical examinations as the control group. The qRT-PCR method was applied to detect the expression of serum miR-183-3p and miR-495-3p. Kaplan-Meier curve was plotted to analyze the relationship between miR-183-3p, miR-495-3p and the prognosis of esophageal patients. ROC was applied to analyze the predictive value of miR-183-3p and miR-495-3p for the prognosis of esophageal cancer patients. COX risk regression model was applied to analyze the factors affecting the prognosis of esophageal cancer patients. Results The expression level of miR-183-3p in the esophageal cancer group was higher than that in the control group, while the expression level of miR-495-3p was lower than that in the control group(t=8.760, 4.054, P<0.001). The expression of serum miR-183-3p in the death group was higher than that in the survival group, while the expression of serum miR-495-3p was lower than that in the survival group(t=3.655, 4.210, P<0.001). Patients with high expression of miR-183-3p had an increased degree of low differentiation and the proportion of clinical stage Ⅲ-Ⅳ of AJCC, while patients with low expression of miR-183-3p had an increased degree of middle and high differentiation and the proportion of clinical stage Ⅰ-Ⅱ of AJCC, and the differences were statistically significant(χ2=10.680, P=0.001; χ2=4.246, P=0.001). Patients with high expression of miR-495-3p had an increased degree of middle and high differentiation and the proportion of clinical stage I-II of AJCC, while patients with low expression of miR-495-3p had an increased degree of low differentiation and the proportion of clinical stage Ⅲ-Ⅳ of AJCC, and the differences were statistically significant(χ2=5.341, P=0.021; χ2=9.320, P=0.002). The 3-year survival rate of patients with high expression of miR-183-3p(67.92%) was lower than that of patients with low expression of miR-183-3p(84.62%)(χ2=5.279, P=0.022), and the 3-year survival rate of patients with low expression of miR-495-3p(64.81%) was lower than that of patients with high expression of miR-495-3p(88.24%)(χ2=9.351, P=0.002). The AUC of serum miR-183-3p, miR-495-3p and mir-495-3p in predicting prognosis of patients with esophageal cancer were 0.763, 0.737 and 0.864, respectively, and the AUC of combined was superior to that of their individual predictive efficacy(Z=2.564, 2.011, P=0.010, 0.043). Low differentiation, AJCC clinical stage III-IV, high expression of miR-183-3p, and low expression of miR-495-3p were risk factors affecting the prognosis of esophageal cancer patients[HR(95%CI)=6.628(2.278-19.288), 5.803(2.261-14.897), 5.130(2.187-12.034), 6.152(1.951-19.401)]. Conclusion Serum miR-183-3p is highly expressed and miR-495-3p is low in esophageal cancer patients. The expression of miR-183-3p and miR-495-3p is related to the degree of tumor differentiation and clinical stage of AJCC in patients, and can be used as biological indicators to predict prognosis.

Objective To compare the therapeutic effects of lansoprazole and rabeprazole on postoperative reflux esophagitis in patients with esophageal cancer. Methods Two hundred and two patients with postoperative reflux esophagitis diagnosed in our hospital from August 2019 to October 2023 were randomly divided into experimental group(n=101) and control group(n=101). The control group was given routine support therapy and rabeprazole sodium enteric-coated capsule oral treatment, while the experimental group was given routine support therapy and lansoprazole capsule oral treatment. The therapeutic effects and adverse drug reactions were compared between the two groups after 4 weeks of treatment, and the levels of digestive function related indexes(Gas, MTL, CGRP) and serum inflammation related indexes(IL-4, IL-6, IL-17, IL-23) were compared between the two groups. Results There was no significant difference in the total effective rate between the test group and the control group(P>0.05). After 4 weeks of treatment, the levels of Gas and MTL in the test group were higher than patients in the control group, while CGRP was signicantly lower than patients in the control group(t/P=9.550/<0.001, 7.735/<0.001, 12.398/<0.001). The serum levels of IL-6, IL-17 and IL-23 in the test group were significantly lower than patients in the control group, while IL-4 was higher(t/P=13.039/<0.001, 22.533/<0.001, 7.635/<0.001, 7.682/<0.001). There was no significant difference in the incidence of total adverse reactions between the two groups(P>0.05). Conclusion Both lansoprazole and rabeprazole can significantly relieve the symptoms of postoperative reflux esophagitis in patients with esophageal cancer, in which lansoprazole can better improve the digestive function, reduce the level of inflammation, which has a broader prospect of clinical application.

Objective To investigate the efficacy of radiotherapy combined with Paporizumab in the treatment of recurrent esophageal cancer and its effect on T lymphocytes and tumor markers. Methods Thirty-three patients with recurrent esophageal cancer who underwent three-dimensional conformal intensity-modulated radiotherapy(IMRT) in the Department of Thoracic and Abdominal Radiotherapy, Affiliated Tumor Hospital of Xinjiang Medical University from September 2020 to September 2023 were selected as the control group, and 33 patients with recurrent esophageal cancer who underwent IMRT combined with carrelizumab in the same period were selected as the observation group. Both groups were treated for 6 weeks, and then the clinical efficacy of the patients was evaluated. Both groups were treated for 6 weeks, and the clinical efficacy of the patients was evaluated at 6 weeks of treatment. T lymphocyte subsets[CD3 cells(CD3+), CD4 cells(CD4+), CD8 cells(CD8+)], tumor proliferation-related factors [vascular endothelial growth factor(VEGF), matrix metalloproteinase-9(MMP-9), transcription factor Yin and Yang 1(YY1)], tumor markers[carbohydrate antigen 125(CA125), carcinoembryonic antigen(CEA), squamous cell carcinoma antigen(SCC)]were compared between the two groups before treatment and 6 weeks after treatment. The occurrence of toxic and side effects during treatment was recorded and compared between the two groups. Results After treatment, the total effective rate of the observation group [96.97%(32/33)] was higher than that of the control group [75.76%(25/33)](χ2/P=4.632/0.031). After treatment, VEGF, MMP-9, YY1, CA125, CEA and SCC in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group(t/P=4.598/<0.001,3.317/<0.001,4.664/<0.001). After treatment, CD8+ was lower than that in the control group, CD3+ and CD4+ in the observation group were significantly higher than those in the control group(χ2/t/P=7.229/<0.001,6.388/<0.001,6.157/<0.001,5.322/<0.001,5.116/<0.001,2.479/0.016).During the treatment, the incidence of toxic and side effects in the two groups was compared(χ2/P=0.471/0.492). Conclusion Radiotherapy combined with Pablizumab can more effectively reduce the levels of tumor proliferation-related factors and tumor markers, improve the clinical efficacy, improve the immune function of patients, and will not significantly increase the risk of toxic and side effects.

Objective To investigate the expression of soluble interleukin-2 receptor(sIL-2R) and Eotaxin-1 in the serum of gastric cancer patients and their correlation with Helicobacter pylori(Hp) infection. Methods One hundred and eighteen gastric cancer patients admitted to the Department of Gastroenterology at Beidahuang Group General Hospital from July 2021 to August 2023 were selected as the study group, and 107 patients with benign gastric lesions during the same period were selected as the control group. ELISA was applied to detect the expression levels of serum sIL-2R and Eotaxin-1; Hp detector was applied to detect Hp infection; Spearman method was applied to analyze the correlation between serum sIL-2R, Eotaxin-1 expression levels and Hp infection in patients. Results The expression levels of serum sIL-2R and Eotaxin-1 in the study group were higher than those in the control group(t=8.417, 7.287, P<0.001); The levels of sIL-2R and Eotaxin-1 in the serum of patients with low differentiation, lymph node metastasis, and TNM stage Ⅲ+Ⅳ were higher than those in patients with medium/high differentiation, no lymph node metastasis, and TNM stage Ⅰ+Ⅱ(t=2.966, 3.164, 2.631, P=0.004, 0.002, 0.010)(t=2.232, 2.509, 2.613, P=0.028, 0.013, 0.010); the positive rate of Hp in the study group was higher than that in the control group(χ2=16.069,P<0.001); the expression levels of serum sIL-2R and Eotaxin-1 in patients with Hp infection were higher than those in Hp negative patients(t=2.111, 5.994, P=0.037, <0.001); Hp infection was positively correlated with serum sIL-2R and Eotaxin-1 expression levels(r=0.405, 0.515, P<0.001). Conclusion The expression levels of sIL-2R and Eotaxin-1 in serum are elevated in gastric cancer patients, and there is a correlation between the two and Hp infection.

Objective To investigate the expression of serum Cystatin SN(CST1) and junctional adhesion molecule 2(JAM2) in non-small cell lung cancer(NSCLC) patients and their diagnostic and prognostic value in NSCLC. Methods One hundred and twelve NSCLC patients admitted to the Oncology Department of the 926th Hospital of the Chinese People's Liberation Army Joint Logistics Support Force from February 2019 to February 2021 were selected as the NSCLC group, 60 patients with benign lung diseases were selected as the non NSCLC group, and 60 healthy individuals who underwent physical examinations at the same time in the hospital were selected as the healthy control group. ELISA was used to measure serum CST1JAM2 level. Kaplan-Meier curve was used to compare the prognosis of NSCLC patients with different CST1 and JAM2 expression levels. COX regression was used to analyze the independent risk factors for survival and prognosis of NSCLC patients. The receiver operating characteristic curve was used to analyze the diagnostic value of serum CST1 and JAM2 for NSCLC. Results Compared with the non-NSCLC group and the healthy control group, the serum CST1 level in the NSCLC group was higher, while the serum JAM2 level was lower, and the differences were statistically significant(t/P=57.041/<0.001, 54.550/<0.001; 31.641/<0.001, 30.203/<0.001); NSCLC patients with TNM stage Ⅲ and lymph node metastasis had higher serum CST1 level and lower serum JAM2 level, and the differences were statistically significant(t/P=8.842/<0.001,10.070/<0.001,18.243/<0.001, 23.365/<0.001); The 3-year overall survival rates of CST1 high expression subgroup and low expression subgroup were 50.00%(30/60) and 71.15%(37/52), respectively, and the difference between the 2 subgroups was statistically significant(Log Rank χ2=5.897, P=0.015); The 3-year survival rates of JAM2 high expression subgroup and low expression subgroup were 72.73%(40/55) and 47.37%(27/57), respectively, the difference between the 2 subgroups was statistically significant(Log Rank χ2=7.299, P=0.007). Tumor stage Ⅲ, lymph node metastasis and high serum CST1 were risk factors for poor prognosis of NSCLC patients, while high serum JAM2 was a protective factor [HR(95%CI)=1.610(1.007-2.505), 2.263(1.151-6.100), 2.522(1.406-4.563),0.557(0.368-0.844)]; The AUC of serum CST1, JAM2 and their combination in predicting the prognosis of NSCLC were 0.816, 0.862 and 0.924, respectively. The AUC of the combination of the two was greater than that of serum CST1 or JAM2 alone(Z=5.123, 4.012, all P<0.001). Conclusion The increase of serum CST1 and decrease of JAM2 in NSCLC patients are related to adverse clinical and pathological parameters. The combination of the two has high diagnostic value for the prognosis of NSCLC and is a serum biomarker for evaluating the prognosis of NSCLC patients.